| 项目编号 |
PRJCA012345 |
| 项目标题 |
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC |
| 涉及领域 |
Medical |
| 数据类型 |
biomaker PD-L1; Metabolic data
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
This phase 3 study, CA209816, will evaluate the clinical efficacy of nivolumab plus ipilimumab or nivolumab plus platinum doublet chemotherapy in operable lung cancer. Specifically, this study will compare event free survival (EFS) and compare the pathologic complete response (pCR) rate among participants with Stage IB-IIIa NSCLC treated with nivolumab plus platinum doublet chemotherapy to the EFS and pCR rates in participants treated with platinum-doublet chemotherapy. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2022-10-08 |
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb Company
|
|
2018L02288/2018L02289
|
|
|
|
| 提交者 |
Changli
Wang (wangchangli309@163.com)
|
| 提交单位 |
Tianjin Cancer Hospital |
| 提交日期 |
2022-10-08 |
